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Purpose: The aim of this study was to assess the prevalence of depression among patients with 
epilepsy and to establish the risk factors of depression in that group, with special focus on the 
use of potentially depressogenic medications.
Patients and methods: We studied 289 consecutive patients who visited epilepsy outpatient 
clinic (University Hospital of Krakow) and met inclusion criteria. All patients were screened 
with Beck Depression Inventory (BDI), and those with BDI score $12 were further evaluated 
by a psychiatrist.
Results: Mean age of patients was 35.7 years, and mean duration of epilepsy was 14.7 years. 
Idiopathic generalized epilepsy was diagnosed in 63 patients (21.8%), focal epilepsy was found in 
189 subjects (65.4%), and unclassified epilepsy was diagnosed in 37 patients (12.8%). Frequent 
seizures (.1 per month) were reported in 107 patients (37.0%). Thirty-five patients (12.1%) 
reported an ongoing treatment with one or more of the predefined potentially depressogenic 
medication (β-blockers, combined estrogen and progestogen, corticosteroid, or flunarizine). In a 
group of 115 patients (39.8%) who scored $12 points in BDI, depression was finally diagnosed 
in 84 subjects (29.1%) after psychiatric evaluation. Only 20 of those patients (23.8%) were treated 
with antidepressant. Independent variables associated with the diagnosis of depression in the 
logistic regression model included frequent seizures (odds ratio [OR] =2.43 [95% confidence 
interval, 95% CI =1.38–4.29], P=0.002), use of potentially depression-inducing medications 
(OR =3.33 [95% CI =1.50–7.39], P=0.003), age (OR =1.03 [95% CI =1.01–1.05] per year], 
P=0.005), and use of oxcarbazepine (OR =2.26 [95% CI =1.04–4.9], P=0.038).
Conclusion: The prevalence of depression among consecutive Polish patients with epilepsy 
reached 29.1%. Less than quarter of them received antidepressant treatment at the moment of 
evaluation. Independent variables associated with depression included age, frequent seizures, 
and the use of oxcarbazepine or predefined depressogenic medications.
Keywords: epilepsy, depression, medication, seizures, risk factors, side effects
Introduction
Depression is more common among patients with epilepsy than in the general 
population. The prevalence of depression in community-based studies ranges from 
13% to 36.5%1,2 and reaches up to 54% in patients with refractory epilepsy treated in 
tertiary centers.3 The importance of depression among epilepsy patients is highlighted 
by the fact that it decreases the quality of life to a greater extent than frequent seizures 
themselves.3 Also, only minority of depressed patients with epilepsy are appropriately 
diagnosed and treated,4 which suggests that the awareness of that problem is subop-
timal even in tertiary centers that should routinely screen their patients for symptoms 
of depression.5
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Origin of depression among epileptic patients is most 
likely multifactorial. It may share some determinants with the 
general population (eg, unemployment, marital status), but 
might be also related to epilepsy-specific mechanisms such 
as structural or functional brain damage leading simultane-
ously to depression and epilepsy or, even more importantly, 
may result from the burden of the disease (eg, stigmatization, 
perceived discrimination) or may be treatment related.6
A number of possible risk factors for depression among 
epileptic patients was previously suggested, such as demo-
graphy (older age, female sex),2 clinical factors (frequency 
of seizures, concomitant disorders),5 and sociodemographic 
factors (eg, unemployment or lower education level).6 
Comorbidities such as diabetes, arterial hypertension, 
ischemic heart disease, hyperlipidemia, or chronic respiratory 
disease are associated with depression, both in the general 
population7–9 and specifically in epileptic patients.10 Social 
and demographic issues differ in various societies and 
cultures. Thus, the continuing research in different countries 
seems justified. Only one study related to Polish epileptic 
patients has been published so far and it dealt exclusively 
with focal epilepsy.11
While the possible association between the use of some 
antiepileptic drugs (AEDs) and risk of depression was 
previously noted in regard of phenobarbital, vigabatrin, or 
topiramate,12,13 there are no studies showing a relationship 
between depression in epileptic patients and drugs other 
than AEDs. We have hypothesized therefore that the use of 
those medications may be an additional, so far unrevealed, 
independent risk factor for depression among patients 
with epilepsy.
The aims of this study were to assess the prevalence of 
depression among epileptic patients seen in an outpatient 
epilepsy center and to evaluate the risk factors for depres-
sion in those patients with the special focus on the role of 
depressogenic medications.
Materials and methods
Patients
Participants were recruited from consecutive patients who 
visited outpatient epilepsy clinic in the Department of 
Neurology, University Hospital in Krakow during 1 year.
Inclusion criteria were 1) diagnosis of epilepsy and its 
classification according to the International League Against 
Epilepsy,14,15 2) neuroimaging (magnetic resonance imaging 
or computed tomography, if magnetic resonance imaging was 
contraindicated) performed within 5 years before the inclu-
sion to the study, and 3) informed consent of the patient.
Exclusion criteria were 1) co-occurrence of psychogenic 
nonepileptic seizures; 2) occurrence of tonic, atonic, clonic, or 
atypical absence seizures; 3) thyroid gland disease with abnor-
mal level of thyroxine; 4) malignancies; 5) neurodegenerations 
or other progressive neurological disorders; 6) any change in 
type or dose of AEDs within 1 month before the potential 
inclusion to the study; 7) drug or alcohol abuse; 8) cognitive 
impairment assessed as Mini–Mental State Examination 
score ,24.
The study was performed in accordance with the prin-
ciples of Helsinki Declaration. The protocol of the study was 
approved by the bioethical committee of the Jagiellonian Uni-
versity of Krakow. Each subject obtained the detailed infor-
mation about the goal of the study and the methods to be used 
and gave his/her written informed consent to participate.
Methods
The study had a cross-sectional design. After informed consent 
was provided by the patient, medical history was obtained 
and the neurological examination was performed. Data from 
history, examination, as well as from electroencephalography 
(EEG) and neuroimaging were stored in electronic database. 
An interview was structured and used the questionnaire that 
included information on age, sex, marital status, activity in 
their occupation, etiology and duration of epilepsy, type and 
frequency of seizures, ongoing treatment with AED(s), occur-
rence of comorbidities, ongoing use of any other medication(s), 
family history of epilepsy and/or depression.
Epileptic seizures and epileptic syndromes were classified 
according to the International Classification of Seizures15,16 
and International Classification of Epilepsies and Epilep-
tic Syndromes.17 Accordingly, seizures were classified as 
seizures of focal onset (focal seizures without disorders of 
alertness/consciousness, focal seizures with disorders of 
alertness/consciousness, focal seizures transformed into 
bilateral convulsive seizures), generalized seizures (typical 
absences, myoclonic, and tonic–clonic seizures), and unclas-
sified seizures. Epileptic syndromes were classified into 
localization-related, generalized, or of unknown onset. 
Seizures were classified with the use of history, EEG/video-
EEG, and neuroimaging. If all those sources were taken into 
consideration, the specific type of seizures was diagnosed. 
Otherwise, seizures were left as unclassified. Frequency of 
seizures was assessed with the use of seizure diaries. Data 
on the ongoing treatment with AEDs were collected from 
medical records and history provided by the patient.
The occurrence of depressive symptoms was preliminarily 
assessed with the Polish version of revised Beck Depression 
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Inventory (BDI); it was required that the assessment would 
be done at least 72 hours after the last seizure (to avoid 
postseizure depressive symptoms). Analysis comprised 
depressive symptoms occurring within 1 week preceding the 
assessment. The first version of BDI was validated previously 
in Polish population, and the cut-off score of 12 points was 
indicated as the value suggestive for depression.18 Patients 
who scored at least 12 points in BDI were further consulted 
by the psychiatrists (DD and MS), who established the diag-
nosis of depression according to diagnostic criteria included 
in Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition (DSM-IV) and provided also the diagnosis of 
depressive syndrome according to International Classifica-
tion of Diseases, 10th Edition (ICD-10).
Information on comorbidities and treatment with drugs 
other than AEDs, including antidepressants and previously 
diagnosed epilepsy, and antidepressants was collected dur-
ing interview and further assessed with the medical records. 
We noted the presence of chronic illnesses, including arterial 
hypertension, ischemic heart disease, history of myocardial 
infarction, diabetes, hypercholesterolemia, asthma, as well 
as corrected hypo- or hyperthyreosis. In each patient, we 
recorded all medications taken for 3 months preceding the 
study visit, with special focus on the drugs with the potential 
depression-induction properties. The list of depressogenic 
medications was established according to the literature19 and 
originally included hormones (corticosteroids, estrogens, 
progesterone), β-blockers (mostly propranolol), calcium 
antagonists (flunarizine), some antiparkinsonian drugs 
(levodopa, amantadine), and interferons. In order to compare 
the impact of those medications with other drugs used by 
the patients, the latter ones were collated into the group of 
“other medications”.
Family history of epilepsy and/or depression was estab-
lished in interview with the patient or his/her proxies.
statistical analyses
Qualitative variables were expressed with numbers and 
percentages. Quantitative variables were described with the 
use of a mean and standard deviation (SD). The significance 
of the differences between the qualitative data was analyzed 
using the χ2 test (or with Fisher exact test, where appropri-
ate). Student’s t-test was used to assess differences between 
quantitative variables.
First, univariate analysis of factors that differ between 
patients with and without depression was made. Then, 
analysis of independent factors that influenced the presence 
of depression (dependent variable) was performed by logistic 
regression modeling. An initial model was built with all 
the variables that differed at the level of P,0.2 in univari-
ate analysis. Models were created using stepwise method: 
backward selection with determining criterion likelihood 
ratio for variables selection. A P-value of less than 0.05 was 
considered statistically significant for variables in the final 
model. All the analyses were performed using Statistica v10 
(StatSoft Inc., Tulsa, OK, USA).
Results
general characteristics of the study 
group
Among 467 patients who were seen in the epilepsy clinic 
within the period of the study, 301 subjects met the inclu-
sion criteria and entered the study. After the assessment of 
depressive symptoms with BDI, 12 patients declined further 
assessment by the psychiatrist, and 289 patients were left for 
the final analysis.
Mean age of patients was 35.7 years (SD =14.9). Women 
(n=169) constituted 58.5% of the studied group. One hundred 
sixty-three patients (56.4%) lived alone and 111 subjects 
(38.4%) were active in their profession.
Mean age at the diagnosis of epilepsy was 21.0 years 
(SD =15.3), and the mean duration of epilepsy was 14.7 years 
(SD =11.4). Idiopathic generalized epilepsy was diagnosed in 
63 patients (21.8%), focal epilepsy was found in 189 subjects 
(65.4%), and unclassified epilepsy was diagnosed in 
37 patients (12.8%). One hundred and seven patients (37.0%) 
had frequent seizures (.1 per month), while 90 (31.1%) 
were in remission (no seizure within the previous year). 
Monotherapy was used in 161 subjects (55.7%). The most 
commonly used AEDs included valproate (n=171, 59.2%), 
levetiracetam (n=70, 24.2%), carbamazepine (n=62, 21.5%), 
and lamotrigine (n=39, 13.4%).
Family history of depression was noted in 66 subjects 
(22.8%), and family history of epilepsy was disclosed in 
42 patients (14.5%).
Most common comorbidities included arterial hyperten-
sion (n=39, 13.5%), hypercholesterolemia (n=19, 6.6%), 
ischemic heart disease (n=11, 3.8%), and diabetes (n=7, 
2.4%). Thirty-five patients (12.1%) reported an ongoing 
treatment with any of the predefined potentially depression-
inducing medication (β-blockers, n=27; combined estrogen 
and progestogen, n=6; corticosteroid, n=2; and flunarizine, 
n=1; one person used β-blocker and corticosteroid, one 
person used β-blocker and estrogen with progestogen). 
Twenty-six patients (9%) used antidepressant(s) at the time 
of assessment.
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Other medications used by the studied patients included 
angiotensin convertase inhibitors (n=25), proton pump 
inhibitors (n=9), calcium antagonists other than flunarizine 
(n=30), oral hypoglycemics (n=9), statins (n=21), diuretics 
(n=8), and inhaled β
2
-adrenergic agonists (n=7). One person 
used acenocoumarol, one unspecified immunosuppressant, 
one fibrate, and one thyroxine.
Mean score in BDI was 11.5 (SD =9.7) including 
7.3 points (SD =6.5) in cognitive-affective subscore and 
4.2 points (SD =3.8) in somatic subscore. One hundred fifteen 
patients (39.8%) scored $12 points in BDI and were further 
evaluated by the psychiatrist. After psychiatric evaluation, 
depression was finally diagnosed in 84 subjects (29.1%), ie, 
in 73.0% of subjects with BDI $12 points. Organic mood dis-
order (F06 according to ICD-10) was diagnosed in 38 patients 
(45.2%), depressive episode (F32) in 27 patients (32.1%), 
persistent mood disorder (F34) in 11 patients (13.1%), and 
recurrent depressive disorder (F33) in 8 patients (9.5%). Only 
20 patients diagnosed with depressive symptoms (23.8%) 
were treated with antidepressant(s) at the time of the psychi-
atric assessment.
risk factors analysis
Tables 1 and 2 provide a detailed comparison of recorded 
variables between depressed and nondepressed patients 
with epilepsy. Univariate analysis showed that depressed 
patients were older, more often had a history of depression, 
and used antidepressants more commonly. They were older 
at the onset of epilepsy, and, at the time of evaluation, their 
disease lasted slightly longer. Patients diagnosed with depres-
sion were more commonly treated with oxcarbazepine or 
levetiracetam and were less likely to receive monotherapy. 
Frequent seizures and complex partial seizures were more 
often seen among depressed patients as well, while remission 
was less likely among them.
Patients with focal epilepsy were diagnosed with depres-
sion more often (n=61, [32.3%]) than those with generalized 
epilepsy (n=12 [19.0%], P=0.045). Patients with frequent 
Table 1 Comparison of demographic, clinical, and instrumental findings between depressed and nondepressed patients with epilepsy 
(univariate analysis)
Variable Depressed patients  
(n=84)
Nondepressed patients  
(n=205)
P-value for the 
difference
age 41.3±15.7 33.4±14.0 ,0.001
sex (% of women) 49 (58.3%) 120 (58.5%) 0.97
Marital status (% of living alone) 40 (47.6%) 123 (60.0%) 0.054
education level
Primary school 6 (7.1%) 23 (11.2%) 0.33
Vocational school 23 (27.4%) 38 (18.5%)
high school 40 (47.6%) 102 (49.8%)
college 15 (17.9%) 42 (20.5%)
Occupational activity (% of active) 29 (34.5%) 82 (40%) 0.38
history of depression 23 (27.4%) 6 (2.9%) ,0.001
Use of antidepressant(s) 20 (23.8%) 6 (2.9%) ,0.001
comorbidities
arterial hypertension 14 (16.7%) 25 (12.2%) 0.31
Diabetes 4 (4.8%) 3 (1.5%) 0.11a
ischemic heart disease 5 (6.0%) 6 (2.9%) 0.19a
Myocardial infarction 2 (2.4%) 2 (1.0%) 0.33a
hypercholesterolemia 9 (10.7%) 10 (4.9%) 0.07
asthma 0 6 (2.9%) –
hypothyreosis 2 (2.4%) 2 (1.0%) 0.33a
hyperthyreosis 3 (3.6%) 2 (1.0%) 0.15a
any comorbidity 20 (23.8%) 35 (17.1%) 0.18
Use of potentially depression-inducing medication(s) 20 (23.8%) 15 (7.3%) 0.0001
Use of other medication(s)a 24 (28.5%) 38 (18.5%) 0.06
Family history of epilepsy 20 (23.8%) 46 (22.4%) 0.80
Family history of depression 16 (19.0%) 26 (12.7%) 0.16
BDi total score 20.5±7.9 7.8±7.7 ,0.001
BDi, cognitive-affective subscore 13.3±5.4 4.9±5.1 ,0.001
BDi, somatic subscore 7.1±3.7 3.0±1.5 ,0.001
Notes: aMedications other than antiepileptic drugs or depressogenic medications. Data are presented as n (%) or mean ± standard deviation.
Abbreviation: BDi, Beck Depression inventory.
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Table 2 comparison of epilepsy characteristics between depressed and nondepressed patients with epilepsy (univariate analysis)
Variable Depressed patients  
(n=84)
Nondepressed patients  
(n=205)
P-value for the 
difference
age at onset of epilepsy 24.9±17.2 19.4±14.2 0.006
Disease duration 16.4±11.9 14.0±11.1 0.10
Type(s) of seizures
simple partial 11 (13.3%) 34 (16.6%) 0.46
complex partial 49 (58.3%) 80 (39.0%) 0.003
secondary generalized 52 (61.9%) 107 (52.2%) 0.13
absence 9 (10.7%) 22 (10.7%) 0.99
Myoclonic 5 (6.0%) 22 (10.7%) 0.20
Primary generalized 13 (15.5%) 47 (22.9%) 0.16
Unclassified 9 (10.7%) 24 (11.7%) 0.81
Treatment
Valproate 43 (51.2%) 128 (62.4%) 0.08
carbamazepine 15 (17.9%) 47 (22.9%) 0.34
Phenobarbital 3 (3.6%) 7 (3.4%) 0.59
Primidone 1 (1.2%) 5 (2.4%) 0.44
Phenytoin 4 (4.8%) 4 (2.0%) 0.17
clonazepam 5 (6.0%) 4 (2.0%) 0.08
lamotrigine 13 (15.5%) 26 (12.7%) 0.53
Topiramate 16 (19.0%) 22 (10.7%) 0.057
Vigabatrin 0 2 (1.0%) –
levetiracetam 27 (32.1%) 43 (21.0%) 0.044
Tiagabine 0 2 (1.0%) –
gabapentin 2 (2.4%) 12 (5.9%) 0.17
Oxcarbazepine 17 (20.2%) 19 (9.3%) 0.01
ethosuximide 0 2 (1.0%) –
clobazam 1 (1.2%) 0 –
Number of aeDs
Monotherapy 37 (44.0%) 124 (60.5%) 0.011
2 33 (39.3%) 49 (23.9%) 0.008
3 13 (15.5%) 29 (14.4%) 0.77
4 1 (1.2%) 2 (1.0%) 0.64
5 0 1 (0.5%) –
Frequent seizures (.1 per month) 45 (53.6%) 62 (30.2%) 0.0002
No seizures in the previous year 19 (22.6%) 71 (34.6%) 0.045
Note: Data are presented as n (%) or mean ± standard deviation. 
Abbreviation: aeD, antiepileptic drug.
seizures (n=107) had depression much more commonly than 
patients with remission (n=90) (42.1% vs 21.1%, respec-
tively; P=0.002).
Multivariate analysis revealed several independent 
variables associated with the diagnosis of depression at the 
moment of evaluation. These included: frequent seizures (odds 
ratio [OR] =2.43), use of potentially depression-inducing 
medication(s) (OR =3.33), age (OR =1.03 for each year 
more), and use of oxcarbazepine (OR =2.26) (Table 3).
Additionally, we have explored possible association 
between the use of depressogenic medications or oxcar-
bazepine and some clinical features suggestive for more 
severe epilepsy. Patients treated with oxcarbazepine were 
more often affected by frequent seizures than patients who 
did not use that medication (63.9% vs 33.2%, respectively; 
P=0.004). They were also more likely to use polytherapy 
(66.7% vs 41.1%, respectively; P=0.004). Moreover, the 
prevalence of complex partial seizures was greater among 
oxcarbazepine users (61.1% vs 42.3%; P=0.03).
On the other hand, patients who were exposed to depres-
sogenic medications did not differ from their counterparts 
who did not use those drugs in terms of frequent seizures 
(34.3% vs 37.4%, respectively; P=0.72), polytherapy 
(40.0% vs 44.9%, respectively; P=0.59), or prevalence of 
complex partial seizures (54.3% vs 43.3%, respectively; 
P=0.22).
Discussion
By and large, almost 30% of epileptic patients were diagnosed 
with depression in this study, with independent risk factors 
including age, frequent seizures, use of oxcarbazepine, and 
use of some a priori suggested depressogenic medications.
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Table 3 independent predictors of depression among studied patients with epilepsy (logistic regression model with backwards 
elimination)a
Variable Standard  
error
Wald  
statistics
P-value Odds ratio (95%  
confidence interval)
Frequent seizuresb 0.288 9.55 0.002 2.43 (1.38–4.29)
Use of potentially depression-inducing medication(s) 0.405 8.82 0.003 3.33 (1.50–7.39)
agec 0.010 7.99 0.005 1.03 (1.01–1.05)
Use of oxcarbazepine 0.394 4.28 0.038 2.26 (1.04–4.90)
Notes: aThe following variables were removed during consecutive steps of backward elimination: monotherapy (P=0.93), age at onset of epilepsy (P=0.99), duration of disease 
(P=0.83), marital status (P=0.78), hypercholesterolemia (0.62), complex partial seizures (P=0.39), use of medications other than antiepileptic drugs or depressogenic ones 
(P=0.37), use of levetiracetam (P=0.30), use of valproic acid (P=0.24), any comorbidity (P=0.10), use of clonazepam (P=0.06), and use of topiramate (P=0.06). bseizures more 
frequent than 1 per month. cOdds ratio for the difference of 1 year.
Estimates of depression prevalence and incidence among 
patients with epilepsy vary greatly in relation to the set-
ting (tertiary centers vs community-based samples), type 
of epilepsy (all types vs generalized vs focal), and type of 
epileptic syndrome (eg, juvenile myoclonic epilepsy vs 
temporal lobe epilepsy). Prevalence of depression may also 
differ in various countries with some inherent factors play-
ing their own role (eg, level of unemployment, availability 
of social services, model of the family, and its rapid change 
perceived currently in Poland). It seems worth noting that the 
percentage of patients with depression revealed in this study 
(29.1%) is actually very similar to the most recent estimates 
reported in cohort studies among patients with various types 
of epilepsy (22.3%–29.3%).20–23 While it may be argued that 
community-based studies provide more accurate estimates of 
the prevalence of depression, recent systematic review and 
meta-analysis of such studies24 brought very similar findings 
(an overall prevalence of active depression reaching 23.1%, 
with 95% confidence interval of 20.6%–28.3%), which may 
suggest that the cohort studies provide reliable data.
This study did not include a control group of healthy 
subjects as it focused on the risk factors of depression among 
epileptic patients. It is worth noting, however, that the most 
recent population-based study (EZOP-Poland), performed 
in accordance with World Health Organization recom-
mendations, revealed that 3.0% (95% confidence interval: 
2.7%–3.3%) of Polish general population (aged 18–64) is 
affected with depression and that a further 0.6% (95% con-
fidence interval: 0.5%–0.8%) suffers from dysthymia.25
More advanced age was an independent but weak 
(OR =1.03 per each additional year of age) risk factor for 
depression among studied patients, and this corroborated 
previous findings on that topic.2,26 This association might 
stem from the accumulation of all detrimental contributors 
(eg, somatic disorders and perceived disability) with age, as 
well as from the sociodemographic factors (loneliness, lack 
of support, hopelessness).
Frequent seizures (ie, occurring more often than once 
per month) independently increased the risk of depression 
in this study (OR =2.43), which is in agreement with numer-
ous previous studies, including several population-based 
studies6,27 and studies in patients with idiopathic generalized 
epilepsy,28 juvenile myoclonic epilepsy,29 or various types 
of epilepsy.5 Frequent seizures may adversely affect mood 
through a variety of mechanisms, including psychosocial 
factors (eg, unemployment, difficulty to maintain stable 
relationships, stigmatization), iatrogenic influence of poly-
therapy (including increased probability of drug interactions 
and side effects), and some biological determinants for both 
seizures and depression. It is also possible that this asso-
ciation is bidirectional, ie, that the depressed mood affects 
the efficacy of treatment (eg, due to lesser compliance or 
unwillingness to pursue more challenging modifications of 
lifestyle, diet, etc).
The apparent association between the use of oxcarbazepine 
and depressive symptoms among epileptic patients might be 
viewed as an unexpected finding, given the use of oxcarba-
zepine and its closely related compound – carbamazepine – in 
the management of bipolar disorder. According to our find-
ings, however, patients who used oxcarbazepine were more 
likely to exhibit some features suggestive for more severe 
epilepsy. They were more often treated with polytherapy, had 
frequent seizures more commonly, and were more likely to 
experience complex partial seizures. Furthermore, patients 
treated with oxcarbazepine were more frequently living 
alone (70% vs 56%), which is another factor suggested by 
some authors as associated with greater risk of depression 
among epileptic patients.30 Thus, we believe that the use of 
oxcarbazepine reflects the features of more severe epilepsy 
(leading itself to a greater prevalence of depression) rather 
than the impact of medication on their mood.
On the other hand, the possible link between the sever-
ity of epilepsy and the use of depressogenic drugs is highly 
unlikely. The prevalence of clinical features consistent with 
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
17
2.
86
.1
91
 o
n 
06
-M
ay
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2515
Depression and its risk factors in Polish patients with epilepsy
more severe epilepsy (ie, frequent seizures, complex partial 
seizures, or polytherapy) was similar between patients who 
used or did not use depressogenic medications.
The key finding of our study was an association between 
heterogeneous group of potentially depression-inducing 
medications and depression among patients with epilepsy. 
While a number of such medications can be listed, we have 
chosen four classes or individual medications that have been 
used by our patients. The number of patients who used spe-
cific medications potentially inducing depression was small 
in this study; thus, we could only collate data regarding all 
those drugs in one group. As β-blockers were predominant in 
that group of medications (27/35), we performed additional 
post hoc analysis that used β-blockers only and it produced 
the borderline significance in logistic regression model 
(P=0.055), suggesting that either the sample was too small 
to provide definite evidence or that some other drugs also 
contributed to the overall finding.
The depressogenic action of β-blockers is most prob-
ably related to the decrease of noradrenergic activity of the 
brain,31 or alternatively, to the affinity to 5HT1A receptors. 
Association between β-blockers and depression is suggested 
by some studies32 but refuted in others;33 it was shown, how-
ever, that the use of nonselective, highly lipophilic β-blockers 
(eg, propranolol) significantly increases the risk of depressive 
symptoms.31
Female sex hormones can affect mood by the lower-
ing of serotonin concentration secondary to the increased 
monoamine oxidase activity induced by progesterone or 
by the estrogen-induced loss of pyridoxine, resulting in the 
decrease of levels of brain serotonin.34
Depression-inducing properties of flunarizine were 
ascribed either to the dopaminergic blockade or to the 
calcium antagonism.35,36 Corticosteroids have been linked 
to mood disturbances for decades due to their impact on 
cortisol levels.37
While the mechanisms are probably too complex to be 
reliably discerned, it seems prudent not to change the man-
agement strategy in epileptic patients who do not exhibit 
any mood disturbance. At the same time, the recognition 
of depressive symptoms in patients with epilepsy should 
prompt comprehensive evaluation which ought to include 
assessment of depressogenic medications, not necessarily 
associated with nervous system at first glance.
An interesting but controversial link between depres-
sion and epilepsy stems from the phenomenon of “forced 
normalization”, defined as an acute or subacute onset of neu-
ropsychiatric disturbances, including depression, associated 
with remission of clinical seizures and disappearance of 
epileptiform activity in EEG.38 It is hypothesized that the 
regulatory response to frequent seizures leads to altered bal-
ance of GABA-ergic and glutamatergic activity in favor of 
inhibition. Such a change might simultaneously produce some 
neuropsychiatric disturbances (eg, depression). Interestingly, 
the use of some antiepileptic drugs (eg, levetiracetam) was 
reported as the triggering factor for the forced normalization.39 
The design of the current study precluded the longitudinal 
evaluation of the sequence of events required to diagnose this 
phenomenon, but it seems reasonable to consider its assess-
ment in future studies.
The authors acknowledge some limitations of the study. 
The sample size, although relatively small, is actually com-
parable to most previous studies with similar design. While 
it was not a community-based study, it should be stressed 
that the vast majority of epileptic patients in Poland are 
managed in epilepsy clinics rather than by general practi-
tioners. Also, formal psychiatric evaluation was performed 
only in those who scored $12 points in BDI, which may 
seem to underestimate the absolute number of patients with 
depression. On the other hand, this approach resembles 
closely the everyday clinical practice in which patients are 
referred to the psychiatrist after the depressive symptoms 
are revealed during the history-taking or after the use of 
dedicated questionnaires, as was the case in our study. 
The detailed discussion of specific subtypes of depressive 
disorders within the cohort of patients reported here was 
published elsewhere.40
While some independent risk factors for epilepsy had 
been already precisely described, it seems worth focusing on 
the potential depression-inducing medications as the possibly 
avoidable source of depressive symptoms among epileptic 
patients. Therefore, we are currently preparing the study 
which would focus on this topic more specifically, hoping 
to recruit enough patients to assess the relative involvement 
of specific types of medications. Nevertheless, the evidence 
should be considered provisional and should not guide any 
treatment decisions at the time.
Conclusion
The prevalence of depression in the cross sectional sample 
of consecutive Polish patients with epilepsy reached 29.1%. 
Independent variables associated with depression among 
studied patients included age, frequent seizures, the use of 
oxcarbazepine, and treatment with some depression-inducing 
medications (β-blockers, corticosteroids, estrogen with pro-
gestogen and flunarizine).
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